New horizons in anticoagulation: direct oral anticoagulants and their implications in oral surgery

• Víctor Serrano-Sánchez ^[1] ; Jorge Ripollés-de Ramón ^[1] ; Luis Collado-Yurrita ^[1] ; Iris Vaello-Checa ^[1] ; Constantino Colmenero-Ruiz ^[2] ; Alexandra Helm ^[1] ; Maria-José Ciudad-Cabañas ^[1] ; Victoriano Serrano-Cuenca ^[1]
  1. [1] Universidad Complutense de Madrid

     Universidad Complutense de Madrid

     Madrid, España

     
  2. [2] DDS. Faculty of Dentistry of Complutense University of Madrid. Collaborator in the Master in Oral Surgery at the University Hospital of Príncipe de Asturias (UAH)
• Localización: Medicina oral, patología oral y cirugía bucal. Ed. inglesa, ISSN-e 1698-6946, Vol. 22, Nº. 5, 2017
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Thrombotic disorders remain a leading cause of death in the Western World. For decades, vitamin K antagonists used in the prevention of this pathology, such as warfarin or sintrom, were the only oral agents available for long-term anticoagulation, in spite of their disadvantages.

    An electronic database search was carried out on MedLine and The Cochrane Library Plus, without restrictions on the type of study nor dates, in English and Spanish. Abstracts were reviewed, and complete articles if necessary, considering all articles that included recommendations on DOACs and oral surgery.

    In recent years, the so-called “new oral anticoagulants” have been introduced in clinical practice to treat those patients whose medical conditions require long-term anticoagulant treatment, replacing traditional oral anticoagulants.

    The new oral anticoagulants represent new therapeutic options, with a number of advantages such as poor interaction with food, minor drug interactions, and do not require periodic dose adjustments or routine controls. The purpose of this review is to establish an update on the new oral anticoagulants: Dabigatran, Rivarozaban, Apixaban and Edoxaban.